-
I-Mab Poised To Capitalize On Growing Oncology Sector, Needham Says In Bullish Initiation
Monday, March 15, 2021 - 10:53am | 393Read More...Shares of the U.S.-listed Chinese immuno-oncology company I-Mab (NASDAQ: IMAB) offer strong upside potential, according to a Needham analyst. The I-Mab Analyst: Chad Messer initiated coverage of I-Mab shares with a Buy rating and $75 price target. The I-Mab Takeaways: I-Mab has an...
-
Geron's Blood Cancer Candidate Creates Buying Opportunity, Needham Says In Upgrade
Tuesday, April 9, 2019 - 2:50pm | 498Read More...Geron Corporation (NASDAQ: GERN) announced in September that Johnson & Johnson (NYSE: JNJ)'s Janssen unit opted to terminate a collaboration and licensing agreement between the companies for imetelstat, the former's myelofibrosis treatment candidate. In reaction to the...
-
Analysts Defend Esperion As Shares Sell Off Sharply
Thursday, May 3, 2018 - 11:17am | 460Read More...Esperion Therapeutics Inc (NASDAQ: ESPR) stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. While the company hit its primary endpoints with the trial, patients in the test group experienced a higher...
-
Celator Pharma Investors Applaud Needham's New Buy Rating, $24 Target
Tuesday, April 12, 2016 - 2:27pm | 377Read More...Shares of Celator Pharmaceuticals Inc (NASDAQ: CPXX) are nearing their 52-week high after Needham started coverage of the stock with a Buy rating and $24 price target, saying the company's Vyxeos could become new standard of care for high risk acute myeloid leukemia. Acute myeloid leukemia...
-
Analysts Weigh In: Regado Future 'Unclear' As Shares Fall Below Cash Value
Monday, August 25, 2014 - 2:34pm | 206Read More...Regado Biosciences (NASDAQ: RGDO) plunged after safety concerns permanently halted trials on its lead drug candidate for preventing complications from angioplasty surgery. Deutsche Bank's Robyn Karnauskas downgraded the shares to Hold from Buy and slashed her target 87 percent to $2, from $14....
-
Vivus Tumbles 70% on FDA Disapproval; Piper Jaffray Urges You to Buy Arena (ARNA, VVUS)
Friday, July 16, 2010 - 10:07am | 144Read More...The FDA Advisory Committee voted 9 to 7 yesterday against approval of Vivus' (NASDAQ: VVUS) Qnexa, a fat-fighting pill. Vivus tumbled 60% today on the news to just over $5. Concerns arose over Qnexa's safety, especially suicide and cardiovascular risk at high doses. Piper Jaffray believes that even...
-
Piper Jaffray Impressed By New Regeneron Drugs (REGN)
Thursday, July 1, 2010 - 9:36am | 110Read More...Piper Jaffray analysts Chad Messer and Edward Tenthoff visited Regeneron (NADAQ:REGN) yesterday, where they were impressed by the biotech company's new product lines. Piper Jaffray said, "Regeneron fits our thesis that well financed biotech companies with innovative drug launches over the next 2...
-
Cytori Therapeutics (NASDAQ: CYTX) Shares Fall On News Of Launch Delay
Thursday, March 18, 2010 - 8:51am | 129Read More...Analysts at Piper Jaffray reiterated their underweight rating for Cytori Therapeutics (NASDAQ: CYTX) on news that Cytori’s Celution system launch will be delayed. Analysts at Piper Jaffray noted that “shares of CYTX are down 36% over the last four trading sessions since Cytori reported that the FDA...
